Abcam, ab258686, Human SMAD7 (MADH7) knockout HeLa cell lysate

Size: 1Kit
SMAD7 KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon4.
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon4.,
Disease:Adenocarcinoma

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-SMAD7, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
MADH7 also known as SMAD7 is an intracellular protein that acts as an inhibitor in the signaling pathway of the TGF-beta (transforming growth factor-beta) family. This protein has a molecular mass of approximately 46 kDa and is widely expressed with a significant presence in tissues involved in immune response and development. SMAD7 directly interacts with receptor-regulated SMADs (R-SMADs) preventing their phosphorylation and consequent nuclear translocation effectively halting further signal transduction.
Biological function summary
SMAD7 functions to regulate the TGF-beta signaling pathway by operating as a negative feedback mediator. It binds to TGF-beta receptors recruiting E3 ubiquitin ligases which promote receptor degradation. SMAD7 is not part of complex large-scale multi-protein assemblies but is essential in modulating the pathway's activity. Its balance controls important processes like cell proliferation differentiation and apoptosis across varied biological contexts.
Pathways
SMAD7 strongly influences the TGF-beta and BMP (bone morphogenetic protein) signaling pathways. SMAD7 blocks TGF-beta signaling by interfering with the activity of R-SMADs such as SMAD2 and SMAD3 and it modulates the BMP pathway by interacting with SMAD1 and SMAD5. Its regulatory roles are tightly integrated within these pathways highlighting its importance in cellular homeostasis and response to extracellular signals.
SMAD7 has links to inflammatory conditions and cancer. Its dysregulation can lead to heightened TGF-beta signaling which may contribute to conditions like fibrosis and can enhance tumor progression by affecting cancer cell dynamics and the tumor microenvironment. In these scenarios abnormal SMAD7 function can associate with proteins such as SMAD3 in fibrosis while in cancer its association with proteins like SMAD4 disrupts normal growth control and cellular response.